Glioblastoma is nearly always fatal, but not universally so. About 5% to 7% of people are still alive five years after diagnosis, and a small number survive well beyond that. The median survival with standard treatment is around 14 months, meaning half of patients live longer and half live shorter than that mark. These numbers are sobering, but they also mean that calling glioblastoma “100% fatal” overstates the case slightly.
What the Survival Numbers Actually Look Like
Without treatment, glioblastoma typically kills within a few months. With surgery followed by radiation and chemotherapy, the median survival stretches to roughly 14 months. In a large study at Seoul National University Hospital tracking 600 newly diagnosed patients, 18% were alive at three years and about 8% made it past five years. Those numbers align with Mayo Clinic’s estimate of 5% to 7% reaching the five-year mark in large studies.
These are population averages, and individual outcomes vary widely. Some patients decline rapidly within months. Others, classified as long-term survivors, live three years or more. A small fraction live a decade or longer. Researchers studying these long-term survivors have found no single characteristic that explains why they do better. It appears to be a combination of tumor biology, age, overall health, and how completely surgeons can remove the tumor.
Tumor Biology Matters More Than Most People Realize
Two glioblastomas that look identical on an MRI can behave very differently based on their genetic makeup. Two molecular markers stand out as especially important for prognosis.
The first is a chemical modification in the tumor’s DNA repair system. When a tumor has this modification (called MGMT promoter methylation), it struggles to fix the damage that chemotherapy inflicts on it, making treatment more effective. Patients whose tumors carry this change had a median survival of about 504 days (roughly 17 months) compared to 329 days (about 11 months) for those without it. In younger patients under 53, the gap was even wider: 639 days versus 434 days.
The second key marker involves a mutation in a gene called IDH. The current classification system actually separates brain tumors based on this mutation. Tumors without the IDH mutation (called IDH-wildtype) are classified as glioblastoma, with a median survival of 12.3 months. Tumors with the mutation are now classified as a different diagnosis entirely, IDH-mutant astrocytoma, and carry a median survival of 38.4 months. If you’ve seen older statistics showing some glioblastoma patients surviving many years, some of those cases likely involved IDH-mutant tumors that would today be categorized differently. This reclassification means modern glioblastoma survival statistics may look slightly worse than older ones, even though treatment has improved.
How Glioblastoma Is Treated
The standard approach starts with surgery to remove as much of the tumor as safely possible. Because glioblastoma grows with finger-like projections into surrounding brain tissue, complete removal is rarely achievable. Surgeons aim to take out as much as they can without damaging critical brain areas.
After surgery, patients receive about four to six weeks of daily radiation combined with oral chemotherapy. Once that phase ends, chemotherapy continues in monthly cycles, typically five days on followed by 23 days off, for six cycles. This protocol has been the backbone of glioblastoma treatment since 2005.
A newer addition uses a portable device that delivers low-intensity electrical fields to the scalp, disrupting the ability of cancer cells to divide. Patients wear adhesive arrays on their shaved heads for at least 18 hours a day. In a clinical trial of nearly 700 patients, adding this device to standard chemotherapy pushed median survival from 16 months to about 21 months, a meaningful gain for this disease. The five-month improvement made it part of the recommended treatment plan at many cancer centers.
When the Tumor Comes Back
Glioblastoma recurs in the vast majority of patients, and this is the phase where treatment options narrow considerably. Median survival after recurrence is less than one year, and there is no agreed-upon standard approach.
Options include a second surgery, which offers a median survival of about nine months afterward. Re-irradiation is another possibility: a meta-analysis of over 2,000 patients found 73% were alive six months after re-irradiation, dropping to 36% at one year. An anti-angiogenic drug that cuts off the tumor’s blood supply has FDA approval for recurrent glioblastoma and can shrink tumors in roughly 28% to 38% of patients, but it has not been shown to meaningfully extend overall survival in randomized trials. It does help manage symptoms and slow progression for a period.
Clinical trials become especially important at recurrence. Several vaccine-based approaches are in late-stage testing. One dendritic cell vaccine showed a two-year survival rate of about 21% compared to 10% in controls, and a five-year rate of 13% compared to 6%. However, it failed to meet its primary endpoint of delaying tumor progression. Another promising vaccine targeting a specific protein on tumor cells was discontinued after a large Phase III trial showed no survival benefit. The search for effective treatments at recurrence remains one of the most active areas of neuro-oncology research.
What Affects an Individual’s Outlook
Several factors consistently predict better or worse outcomes. Younger age is one of the strongest. Patients under 50 tend to do better than those over 65, partly because younger patients tolerate aggressive treatment more easily and partly because their tumors are more likely to carry favorable genetic features.
How much tumor surgeons can remove also matters. Patients who undergo what’s called a gross total resection, where all visible tumor is removed on post-surgical imaging, live longer than those who have only a partial removal or biopsy. In patients with favorable genetic markers who also had complete resections, median survival reached about 18 months.
A patient’s functional status at diagnosis, essentially how well they can carry out daily activities, is another strong predictor. Someone who is active and independent at the time of diagnosis will generally fare better than someone who is already significantly impaired.
Quality of Life During Treatment
Because glioblastoma affects the brain, it can cause symptoms beyond what most cancers produce. Seizures, personality changes, fatigue, difficulty with speech or movement, and cognitive decline are common at various stages. Treatment itself adds side effects: fatigue from radiation, nausea and lowered blood counts from chemotherapy, and skin irritation from the electrical field device.
Palliative care, focused on managing symptoms and maintaining quality of life, plays a critical role throughout treatment. Research consistently shows it should be introduced early, ideally near the time of diagnosis rather than only at the end of life. In practice, this often doesn’t happen. One study found 20% of patients with malignant brain tumors weren’t referred to palliative care until just one week before death, and 59% were referred within 30 days of dying. Early involvement of a palliative care team can help with symptom management, emotional support, and planning for the future while patients are still well enough to participate in those conversations.
Family members in one survey said they preferred these planning conversations to begin at the time of diagnosis. Patients themselves were more divided, with some preferring to wait until after the initial treatment phase. There is no single right answer, but having the option matters.